Pharmacokinetics of amrubicin in lung cancer patients with impaired hepatic function

Yamamoto, 2009, Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin, Drug Des. Devel. Ther., 2, 189 Morisada, 1989, Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts, Jpn. J. Cancer Res., 80, 69, 10.1111/j.1349-7006.1989.tb02247.x Noda, 1998, Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs, Investig. New Drugs, 16, 121, 10.1023/A:1006088907271 Chan, 1980, Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis, Cancer Res., 40, 1263 Johnson, 1992, Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters, Br. J. Cancer, 65, 751, 10.1038/bjc.1992.158 Morris, 1989, Alteration in doxorubicin and doxorubicinol plasma concentrations with repeated courses to patients, Ther. Drug Monit., 11, 380, 10.1097/00007691-198907000-00002 Inoue, 1989, Phase I and pharmacokinetic study of SM-5887, a new anthracycline derivative, Investig. New Drugs, 7, 213, 10.1007/BF00170860 Donelli, 1998, Pharmacokinetics of anticancer agents in patients with impaired liver function, Eur. J. Cancer, 34, 33, 10.1016/S0959-8049(97)00340-7 Schaaf, 2006, Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction, Clin. Cancer Res., 12, 3782, 10.1158/1078-0432.CCR-05-2152 Tani, 2005, Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride, Xenobiotica, 35, 1121, 10.1080/00498250500342746 Sumitomo Dainippon Pharma Co., Ltd. Calsed® for Injection [Interview form] (in Japanese). 〈http://www.info.pmda.go.jp/go/interview/2/400093_4235406D1020_2_013_1F.pdf〉, 2014. (accessed 18.09.15). Sumitomo Pharmaceuticals Co., Ltd. Calsed® (amrubicin hydrochloride) [Product information] (in Japanese). 〈http://www.pmda.go.jp/drugs/2002/P200200013/index.html〉, 2002. (accessed 18.09.15). Nagata, 2013, C609T polymorphism of NADPH quinone oxidoreductase 1 correlates clinical hematological toxicities in lung cancer patients treated with amrubicin, Clin. Med. Insights Oncol., 7, 31, 10.4137/CMO.S10839 Stewart, 1989, Altered protein binding of etoposide in patients with cancer, Clin. Pharmacol. Ther., 45, 49, 10.1038/clpt.1989.8 Nakai, 1998, Studies on the metabolic fate of amrubicin hydrochloride (SM-5887), a novel antitumor agent (I): blood concentration, distribution, metabolism and excretion after a single intravenous administration to rats, Drug Metab. Pharmacokinet., 13, 61, 10.2133/dmpk.13.61